InvestorsHub Logo
Followers 6
Posts 29
Boards Moderated 0
Alias Born 06/02/2020

Re: None

Thursday, 06/04/2020 3:14:34 PM

Thursday, June 04, 2020 3:14:34 PM

Post# of 130
EXPECT A HUGE JUMP IN THIS STOCK.. ... Rumor that their revenues for Q2 are WAY WAY WAY up - do you think this was because of all the Plaquenil hoarding? I've heard they are putting out studies saying it doesn't work just so they can provide limited inventory to healthcare workers. Hospitals here are still trying to get their hands on Plaquenil. Other countries have ordered Plaquenil to the point where there is a huge shortage now for it's regular indicated uses.

ALSO - They just acquired a new drug alprostadil in Q2 - this has boosted revenues significantly as well ($33+ Million).

The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

Alprostadil is marketed under the brand names of Prostavasin®, Viridal®, Vasaprostan® and Edex®.

Combined sales of all alprostadil brands generated approximately $33.3 million in revenue in 2019 in the territories where ADVANZ PHARMA will hold the rights.

https://www.otcdynamics.com/cxrxf-advanz-pharma-corp-limited-closes-acquisition-of-the-rights-to-a-portfolio-of-alprostadil-products-from-ucb-s-a-for-83-million/?utm_campaign=twitter&utm_medium=twitter&utm_source=twitter

FYI all that fake news are about delisting - well hey it's still listed lol. The shorts really worked hard on that one. ADVANZ PHARMA Corp. is a multi-national pharmaceutical company headquartered in London. They aren't delisting anytime soon lol... they simply just changed their name. This stock is way undervalued based on the potential increase in revenues from alprostadil alone!
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.